Kazia Therapeutics Logo
AU000000KZA9
A2H8QW
KZA.AX

Kazia Therapeutics

Prévisions

Acheter
  1
Conserver
  1
Vendre
  0

Discussions dans la communauté

Il n'y a pas encore de discussion sur cet actif.

Lancer une discussion

  • Kazia Therapeutics announces capital raise of about $40m, shares fall

    Kazia Therapeutics said it will sell 2,580,000 ADS at $15.50 each, expecting gross proceeds of around $40m before fees. In addition, series A and series B warrants are being offered, the exercise of which could generate a further roughly $80m; exercise conditions are tied to the release of clinical trial data for certain breast cancer subtypes. The funds are intended primarily to finance the clinical development of lead candidate Paxalisib and to provide working capital. The offering, accompanied by Leerink Partners, Guggenheim, BTIG and Needham, is expected to close around August 31, 2026; the ADRs fell about 6.2% in premarket trading. » Plus sur de.investing.com


  • Kazia: Paxalisib shows high response rate in metastatic triple-negative breast cancer

    In an ongoing phase 1b study of Paxalisib in combination with pembrolizumab and chemotherapy, six evaluable patients with metastatic triple-negative breast cancer derived clinical benefit. Five of the six patients achieved an objective response (1 complete, 4 partial remissions; objective response rate 83%), and the remaining patient had disease stabilization; responses occurred about three months after randomization and involved, among others, lung, liver, bone, lymph node and CNS lesions. Marked median reductions in circulating tumor cell clusters (83%) and terminally exhausted T cells (51%) were observed, without serious adverse events attributed to Paxalisib. Recruitment is expected to continue until July 2027, with interim results announced for 2026 and 2027. » Plus sur de.investing.com


  • Kazia Therapeutics reports promising preclinical data on protein degrader NDL2

    Kazia Therapeutics released preclinical data on NDL2, a potential first-in-class protein degrader designed to eliminate nuclear PD-L1. In triple-negative breast cancer models, NDL2 reduced tumor volume as monotherapy by 49% and in combination with anti-PD-1 by 73%, and reduced lung metastases by 50%. The program showed no observed toxicity; IND-enabling studies are ongoing and first clinical trials are planned for 2027, with additional data expected in 2026. » Plus sur de.investing.com


  • Kazia Therapeutics meets Nasdaq listing requirements again, hearing canceled

    Kazia Therapeutics reports that it has again met Nasdaq listing requirements, resulting in the cancellation of the hearing scheduled for January 8, 2026. The company has now satisfied the alternative minimum requirement of $2.5 million in stockholders’ equity under Listing Rule 5550(b)(1). Its American Depositary Shares remain listed on the Nasdaq Capital Market. » Plus sur de.investing.com


  • Kazia Therapeutics secures 46.5 Mio. USD through private placement and meets Nasdaq requirement

    Kazia Therapeutics raised net proceeds of approximately 46.5 million USD through a private placement. The company sold 4,530,854,000 common shares at 0.01 USD each and issued pre-funded warrants for up to 938,490 ADS at 4.9999 USD each; each ADS represents 500 common shares. Konik Capital Partners acted as placement agent and also received warrants to purchase up to 700,013 ADS at 7.50 USD, exercisable after 180 days with a five-year term. Kazia expects the transaction to result in equity above the 2.5 million USD minimum required for continued listing on the Nasdaq Capital Market and will notify the Nasdaq Hearings Panel of the restoration of compliance. » Plus sur de.investing.com

Données financières

Au cours de la dernière année, Kazia Therapeutics a réalisé un chiffre d'affaires de 1,43 M € et un bénéfice net de -16,65 M €

(EUR) 2024
YoY
Chiffre d'affaires 1,43 M 423 466,03 %
Bénéfice brut 1,43 M 423 466,03 %
Bénéfice net -16,65 M 33,27 %
EBITDA -16,64 M 22,38 %

Données fondamentales

Indicateur Valeur
Capitalisation boursière
11,49 M €
Nombre d'actions
236,35 M
Plus haut/bas sur 52 semaines
0,15 € - 0,031 €
Dividendes Non
Bêta
2,13
Ratio P/E
-0,01
Ratio PEG
0,00
Ratio P/B
0,01
Ratio P/S
128,14

Profil de l'entreprise

Kazia Therapeutics Limited, une entreprise de biotechnologie spécialisée en oncologie, développe des médicaments anticancéreux. Son candidat au développement principal est le Paxalisib, une petite molécule inhibitrice du pathway PI3K/Akt/mTor capable de franchir la barrière hémato-encéphalique, développée comme thérapie potentielle contre le glioblastome. La société développe également l'EVT801, un nouveau médicament à l'étude pour diverses formes de cancer. L'entreprise était auparavant connue sous le nom de Novogen Limited et a changé de nom pour devenir Kazia Therapeutics Limited en novembre 2017. Kazia Therapeutics Limited a été constituée en 1994 et a son siège à Sydney, en Australie.

Nom
Kazia Therapeutics
PDG
John E. Friend II,
Siège social Sydney, nsw
Australie
Site web
Introduction en bourse
30/09/1994
Employés 12

Symboles boursiers

Bourse Symbole
Australian Securities Exchange Ltd
KZA.AX
Frankfurt
NV9.F
🍪

Parqet  utilise des cookies. En savoir plus